Bringing Open Science to Alzheimer’s and Dementia Clinical Trials

Raising the bar on data and biosample sharing from AD/ADRD clinical trials
Laurie Ryan, Chief, Clinical Interventions and Diagnostics Branch, and Suzana Petanceska, Director, Office for Strategic Development and Partnerships, Division of Neuroscience
NIA’s increased funding for Alzheimer’s disease and related dementias (AD/ADRD) research has allowed the continued expansion and diversification of our drug development portfolio and translational infrastructure programs to help advance future therapeutics.

Implementing best practices for sharing data, methods, and biosamples is at the core of NIA’s next-generation clinical trials infrastructure. If you are working on a clinical trial application, be sure to plan ahead, budget, and communicate with your program officer on how you will approach data and biosample sharing! Read the full blog post.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.